(VIANEWS) – ELIS (ELIS.PA), NAVAMEDIC (NAVA.OL), REACH SUBSEA (REACH.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ELIS (ELIS.PA)
77.2% sales growth and 5.03% return on equity
Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It also provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It primarily serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. Elis SA was founded in 1883 and is headquartered in Saint-Cloud, France.
Earnings Per Share
As for profitability, ELIS has a trailing twelve months EPS of €0.02.
PE Ratio
ELIS has a trailing twelve months price to earnings ratio of 956.67. Meaning, the purchaser of the share is investing €956.67 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 29.7%, now sitting on 3.46B for the twelve trailing months.
Volume
Today’s last reported volume for ELIS is 66910 which is 83.53% below its average volume of 406314.
More news about ELIS.
2. NAVAMEDIC (NAVA.OL)
72.2% sales growth and 16.31% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr-1.14.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.31%.
Moving Average
NAVAMEDIC’s value is way above its 50-day moving average of kr36.80 and way above its 200-day moving average of kr33.35.
More news about NAVAMEDIC.
3. REACH SUBSEA (REACH.OL)
71.2% sales growth and 16.67% return on equity
Reach Subsea ASA provides subsea services worldwide. The company operates in two segments, Oil & Gas and Renewable/Other. It offers inspection, maintenance, and repair services, such as structural inspections, WROV operation, SCM changeout, scale squeeze operations, water injection, ready for operation, subsea equipment maintenance, repair, commissioning, and boulder clearance. The company also provides asset integrity/pipeline inspection services; survey services, including geophysical, geotechnical, UXO, environmental, hydrography, and archaeology; and engineering and project management services. In addition, it offers construction support services comprising vessel, remotely operated vehicles, personnel, survey, and on demand engineering; seabed intervention; boulder clearance; touchdown monitoring; and pre-lay and post- lay survey. Further, the company provides offshore personnel contracting services; geophysical monitoring services, including real-time seismic monitoring, gravitude survey-based 4D gravity, seafloor subsidence monitoring, gravitude depthwatch for seismic nodes, injection integrity monitoring, well drilling, and under control; and environmental monitoring services, such as monitoring CO2 injection and storage, earthquake monitoring and prediction, and geothermal resources assessment and monitoring. It serves oil and gas, renewables, and utilities sectors. The company was formerly known as Transit Invest ASA and changed its name to Reach Subsea ASA in December 2012. Reach Subsea ASA was incorporated in 1909 and is headquartered in Haugesund, Norway.
Earnings Per Share
As for profitability, REACH SUBSEA has a trailing twelve months EPS of kr0.3.
PE Ratio
REACH SUBSEA has a trailing twelve months price to earnings ratio of 14.8. Meaning, the purchaser of the share is investing kr14.8 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.67%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
REACH SUBSEA’s EBITDA is 5.98.
Sales Growth
REACH SUBSEA’s sales growth is 12.6% for the present quarter and 71.2% for the next.
Volume
Today’s last reported volume for REACH SUBSEA is 93953 which is 86.35% below its average volume of 688641.
Moving Average
REACH SUBSEA’s worth is above its 50-day moving average of kr4.33 and way above its 200-day moving average of kr3.96.
More news about REACH SUBSEA.
4. NORWEGIAN AIR SHUT (NAS.OL)
31.3% sales growth and 26.91% return on equity
Norwegian Air Shuttle ASA, together with its subsidiaries, provides scheduled and charter airline services in Norway and internationally. As of December 31, 2021, the company operated a fleet of 70 aircraft. It is also involved in aircraft financing, leasing, and ownership activities; and cargo activities. Norwegian Air Shuttle ASA was founded in 1993 and is headquartered in Fornebu, Norway.
Earnings Per Share
As for profitability, NORWEGIAN AIR SHUT has a trailing twelve months EPS of kr-1022.11.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.91%.
Volume
Today’s last reported volume for NORWEGIAN AIR SHUT is 728272 which is 85.87% below its average volume of 5156860.
Moving Average
NORWEGIAN AIR SHUT’s worth is under its 50-day moving average of kr10.62 and way higher than its 200-day moving average of kr8.91.
Revenue Growth
Year-on-year quarterly revenue growth grew by 94.9%, now sitting on 18.87B for the twelve trailing months.
More news about NORWEGIAN AIR SHUT.
5. MEDISTIM (MEDI.OL)
10.2% sales growth and 33.83% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr3.84.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 73.68. Meaning, the purchaser of the share is investing kr73.68 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.83%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 28, 2022, the estimated forward annual dividend rate is 3.75 and the estimated forward annual dividend yield is 1.33%.
Moving Average
MEDISTIM’s value is way higher than its 50-day moving average of kr237.47 and way higher than its 200-day moving average of kr245.35.
More news about MEDISTIM.
6. MBWS (MBWS.PA)
8.6% sales growth and 3.81% return on equity
Marie Brizard Wine & Spirits SA engages in the producing, marketing, and selling wines and spirits in Western Europe, the Middle East, Africa, Central and Eastern Europe, the Americas, and Asia-Pacific. It primarily offers scotch whisky under the William Peel brand; vodka under the Sobieski and Krupnik brands; wine-based beverages under the Fruits and Wine brand name; liqueurs and syrups under the Marie Brizard brand; and cognac under the Cognac Gautier brand. The company was founded in 1755 and is based in Charenton-le-Pont, France. Marie Brizard Wine & Spirits SA operates as a subsidiary of Compagnie Financiere Europeenne De Prises De Participation SA.
Earnings Per Share
As for profitability, MBWS has a trailing twelve months EPS of €-0.863.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.81%.
Sales Growth
MBWS’s sales growth is 8.6% for the current quarter and 8.6% for the next.
More news about MBWS.
